Rehmann Capital Advisory Group Takes $212,000 Position in GSK plc (NYSE:GSK)

Rehmann Capital Advisory Group acquired a new stake in GSK plc (NYSE:GSKFree Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 4,940 shares of the pharmaceutical company’s stock, valued at approximately $212,000.

A number of other hedge funds also recently made changes to their positions in the business. JTC Employer Solutions Trustee Ltd increased its position in shares of GSK by 71.3% during the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after purchasing an additional 8,800,822 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of GSK by 10.8% during the 4th quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after purchasing an additional 1,465,165 shares in the last quarter. Primecap Management Co. CA increased its position in shares of GSK by 0.3% during the 4th quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock worth $448,032,000 after purchasing an additional 30,600 shares in the last quarter. Morgan Stanley increased its position in shares of GSK by 2.1% during the 3rd quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock worth $273,744,000 after purchasing an additional 156,480 shares in the last quarter. Finally, Provident Trust Co. increased its position in shares of GSK by 53.6% during the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after purchasing an additional 1,297,385 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GSK. Citigroup upgraded shares of GSK to a “strong-buy” rating in a research report on Monday, June 24th. The Goldman Sachs Group began coverage on shares of GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price for the company. Jefferies Financial Group increased their price objective on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday. Finally, Berenberg Bank raised shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.00.

Get Our Latest Stock Analysis on GSK

GSK Trading Down 0.1 %

Shares of NYSE GSK traded down $0.04 during mid-day trading on Wednesday, hitting $38.56. The company’s stock had a trading volume of 2,312,237 shares, compared to its average volume of 3,595,574. The stock has a market cap of $79.91 billion, a price-to-earnings ratio of 13.99, a price-to-earnings-growth ratio of 1.17 and a beta of 0.64. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. GSK plc has a one year low of $33.67 and a one year high of $45.92. The company’s fifty day simple moving average is $42.15 and its 200-day simple moving average is $41.33.

GSK (NYSE:GSKGet Free Report) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.15. The company had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. On average, sell-side analysts anticipate that GSK plc will post 4.1 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a $0.3762 dividend. This represents a $1.50 annualized dividend and a dividend yield of 3.90%. The ex-dividend date is Thursday, May 16th. This is a positive change from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio (DPR) is 53.26%.

GSK Company Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Featured Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.